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A highly objective method, High Performance Liquid Chromatography with Laser Induced Fluorescence (HPLC-LIF) technique
was used to study the protein proﬁles of normal and cervical cancer tissue homogenates. A total of 44 samples including normal
cervical biopsy samples from the hysterectomy patients and the patients suﬀering from diﬀerent stages of the cervical cancer
were recorded by HPLC-LIF and analysed by Principle Component Analysis (PCA) to get statistical information on diﬀerent
tissue components. Discrimination of diﬀerent stages of the samples was carried out by considering three parameters—scores of
factor, spectral residual, and Mahalanobis Distance. Diagnostic accuracy of the method was evaluated using Receiver Operating
Characteristic (ROC) analysis, and Youden’s index (J) plots. The PCA results showed high sensitivity and speciﬁcity (∼100) for
cervical cancer diagnosis. ROC and Youden’s index curves for both normal and malignant standard sets show good diagnostic
accuracy with high AUC values. The statistical analysis has shown that the diﬀerences in protein proﬁles can be used to diagnose
biochemical changes in the tissue, and thus can be readily applied for the detection of cervical cancer, even in situations where a
histopathology examination is not easy because of nonavailability of experienced pathologists.
1.Introduction
Cervical cancer is the second leading cause of cancer mortal-
ity in women in developing countries and seventh in devel-
oped countries [1]. In the earlier stages, the heterogeneous
character of the cellular changes make correct diagnosis dif-
ﬁcult by histopathology, since the pathologist, due to reasons
like “fatigue factor” and lack of experience, may miss the
“patches”inthesample[2,3].Andtheuseofso-calledmark-
ers, like CA 125, CEA, and so forth of no value in cervical
cancer.
Optical spectroscopic methods are highly sensitive in the
detection of the biochemical changes occurring in the tissue
as it proceeds from normal to dysplastic and malignant
conditions [4]. Many groups have studied the ﬂuorescence
spectra of cervical tissue under normal and malignant con-
dition [5–10]. It has been shown that there are noticeable
diﬀerences in the spectrum, arising from changes in tissue
components [11]. In our earlier studies we have analyzed
the protein proﬁles of serum and Pap smear in cervical
malignancy, using HPLC-LIF (High Performance Liquid
Chromatography-LaserInducedFluorescence)[12–14]tech-
nique.Oursystemhasbeenfoundtogivehighlyreproducible
protein proﬁles and is capable of detecting sub-femtomole
quantities of proteins in 20 microlitter of a diluted sample
[15].InthepresentstudywehaveusedtheHPLC-LIFprotein
proﬁling technique for analysis of cervical tissue samples
from normal individuals and cervical cancer patients. The
errorsfromheterogeneousnatureofsampleswereeliminated
by homogenizing the entire sample for protein proﬁling.
Possible subjective nature of histo-pathological diagnosis is
removed by rigorous mathematical/statistical pattern anal-
ysis of the protein proﬁle to give objective diagnosis. The
HPV status of the samples was not considered in the present
experiments, since the main aim of the study was to see2 The Scientiﬁc World Journal
the utility of this method as a preliminary diagnostic tech-
nique in small hospitals and clinics, where facilities for such
examination may not be available. Our studies show that
the tissue protein proﬁle can be used for early detection and
staging of cervical malignancy with high speciﬁcity and sen-
sitivity. The results are presented and discussed in this paper.
2. Methods
2.1. Experimental Setup. The instrumentation has been dis-
cussedindetailelsewhere[14,15].TheHPLCsystemconsists
of an HP 1100 gradient system, Rheodyne 7725 Injection
port and Biphenyl Reversed Phase narrow bore column
(Vydac diphenyl, 2.1 × 250mm, 5µm, 300 ˚ A). Protein
ﬂuorescence was excited by irradiation of the HPLC eﬄuent
inaquartzcapillaryﬂowcellwith257.5nmfromafrequency
doubled Ar+ (Innova 90C FreD, Coherent, California, USA)
laser. Protein proﬁles (Chromatograms) were recorded by
measuring the ﬂuorescence intensity of eluted proteins with
respect to time using double monochromator (Jobin Yvon
DH10 SPEX, New Jersey, USA), Chopper (EG&G model
651),Photomultiplier(HamamatsuR453,NewJersey,USA),
and Lock-in Ampliﬁer (EG&G model 7265) system inter-
faced to a computer. The experimental conditions were Laser
power: 15mW, Chopping Frequency: 20Hz, Monochroma-
tor slits: 2mm (Spectral band pass 8nm), Monochromator
wave length setting: 340nm, PMT voltage: −850 volts, Lock-
in Ampliﬁer time constant: 2 seconds, and Lock in Ampliﬁer
gain: 6dB.
2.2. Sample Collection and Processing. Normal tissue samples
from the squamocolumnar junction of cervix were obtained
from subjects who underwent hysterectomy, for reasons
other than malignancy. Biopsy tissues from cancer patients
were collected from the Department of Obstetrics and
Gynecology, Kasturba Hospital, Manipal. In all cases samples
were used with informed consent of subjects. The approval
of the Institutional Ethics Committee was obtained for these
studies (KHEC-31/2005). The cancer patients were at diﬀer-
ent stages of cancer of the cervix. All samples were collected
from patients who came for treatment. This has resulted in
availability of very few samples from stages other than II
and III, for example, CIN 1, CIS, and so forth, 19 patients
were in stage III, 7 in stage II, 1 stage 0 (CIN I), 1 stage IV,
and 1 from dysplasia of cervix. A total of 15 normal samples
and 29 malignant samples were analyzed. All the malignant
sampleswereofsquamouscellcarcinoma.Thesampledetails
are given in Table 1.
All the samples, irrespective of whether they belonged
to normal or cancer patients, were transported to the lab
immediately after collection in normal saline. In the lab
the tissues were washed with saline several times to remove
any traces of blood. If the tissue samples were to be stored,
they were immediately frozen in liquid nitrogen and stored
at −80◦C in the deep freeze. They were passively thawed
to room temperature just before use. We have veriﬁed that
this procedure did not show any noticeable diﬀerence in the
protein proﬁle of a given sample. The samples were weighed
and minced with 20% wet weight of Tris-EDTA buﬀer. They
Table 1: Sample details.
S. no Stage of cancer Age of the patient
1–15 38–55
16–22 IIB 37–65
23–41 IIIB 35–62
42 IV 60
43 CINI 45
44 CIS 50
were then homogenized by a manual homogenizer (T8 blade
IKA-WERKE),centrifugedat5000rpmfor20minutestwice.
Supernatant was collected through a syringe ﬁtted with
0.45micron ﬁlter. 50 microliters of the sample homogenate
was injected into the HPLC-LIF system, which had a 20
microliter loop.
2.3. Data Analysis. Data processing of recorded protein
proﬁlesinvolvedbackgroundcorrection,smoothing,calibra-
tion, and normalization [14] .A l lp r o t e i np r o ﬁ l e sw e r en o r -
malized with respect to the 1594 seconds peak, which re-
mained more or less constant in all samples. Data analysis
was done by Principal Component Analysis (GRAMS/32,
PLS PLUS/IQ software, in Galactic Corporation, USA).
Diagnosis of tissue type as normal/malignant was achieved
byclassiﬁcationofsamplesusingMatch/NoMatchcondition
of statistical parameters to those of normal and malignant
calibration sets. The details of these have already been
discussed in our earlier paper [14].
To start with, PCA was run with all the samples, (15
normal and 29 malignant), combined, irrespective of wheth-
er they belong to normal or malignant group. The analysis
was performed using 12 factors. PCA was extended further
to see whether a given tissue sample can be identiﬁed more
objectively as belonging to a speciﬁc group, say, normal
or malignant. This is achieved by forming calibration sets
of samples certiﬁed by histopathological examination as
normal or malignant, and comparing the protein proﬁle of
at e s ts a m p l et oe a c hc a l i b r a t i o ns e tt os e ew h e t h e ri tb e l o n g s
to that set or not with a given statistical probability. For this,
a total of 10 samples were taken from the normal set (by
random selection) to make the normal calibration set. A
malignant calibration set was similarly made by taking
randomly 15 samples irrespective of whether they belong to
stageIIorstageIIIsamples.PCAwascarriedoutwitheachof
these calibration sets. The PCA scores were used to simulate
the proﬁles of each sample and the sum of squared residuals-
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calculated. Here I
p
o and I
p
s are the observed and
simulated protein proﬁle intensities, respectively, at point
P on the time axis. All samples were now subjected to the
Match/No match test using the three parameters, scores of
factors, sum of squared residuals, and Mahalanobis distance
[16]. The Mahalanobis distance is normally expressed in
units of standard deviation. It is given by
D2 = (Stest)M−1(Stest)
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Figure 1: (a) Protein proﬁles of Human Serum Albumin (HSA) at diﬀerent concentrations; (b) calibration curve for HSA.
where Stest is the vector of the scores and sum of squared
residuals for a given test sample, and M given by M =
((S S)/(n − 1)),whereS containsthecorrespondingparam-
eters for the calibration set of n standards.
To test whether PCA and Discriminant Analysis can be
usedforobjectivediscriminationbetweenthediﬀerentstages
of malignancy we have also carried out the Match/No Match
test with a standard set from Stage III samples alone. 12
samples were randomly selected from the 19 stage III group
and PCA was carried out with 6 factors. Though sensitivity
and speciﬁcity provide a good measure of the diagnostic
accuracy, it is to be noted that use of these parameters lead
to conﬂicting demands, since to improve one, the other may
have to be sacriﬁced. Estimating diagnostic accuracy is very
important in any kind of diagnostic test, since it gives an idea
of how eﬀectively a diagnostic test can diﬀerentiate disease
from normal condition. In order to arrive at the best values
for sensitivity and speciﬁcity, one can apply the technique
of Receiver Operating Characteristic (ROC) Curve [17]. We
have carried out the estimation of the diagnostic accuracy
for both normal and malignant set results by this method.
One of the important measures of ROC analysis is ﬁnding
Area Under the ROC-Curve (AUC), which evaluates the
overall performance of the diagnostic test and is considered
as the mean value of sensitivity for all the possible values
of speciﬁcity [18]. The ROC curve analysis illustrates the
relationship between the sensitivity and speciﬁcity of a
diagnostic test. It is a measure of the performance of a di-
agnostic test. As already pointed out, the opposite trends of
sensitivityandspeciﬁcitymakeitdiﬃculttoarriveatsuitable
threshold/cutoﬀ values for the test parameters. To remove
the resulting subjectivity of choice of threshold, one can use
the method of Youden’s index [19]. Youden’s index gives an
idea about the optimum threshold/cutoﬀ values of the test
parameters used for screening. Youden’s index J is deﬁned
by J = Sensitivity + Speciﬁcity − 1. Youden’s index curve is a
plot of Youden’s index (J) values vurses diﬀerent operating
thresholds of a test parameter (M distance). It shows the
ideal operating point (threshold), namely, that for which J is
maximum. At this threshold, sensitivity and speciﬁcity pairs
will be having maximum values. At all other points, one or
the other of these will have lower values. We have used the
PCA results with normal and malignant calibration sets (i.e.,
Match/No Match) for these analyses. The ROC curves are
plotted using speciﬁcity and sensitivity values corresponding
to selected cutoﬀ thresholds for M distance. The Youden’s
indices are calculated for diﬀerent M distances for thresholds
and plotted as Youden’s indices versus thresholds.
3. Results
3.1. Visual Analysis of Protein Proﬁles. The HPLC-LIF system
used for the present study is highly sensitive, being capable
of detecting trace amounts of proteins (of the order of femto
moles) in microliter volume of sample. We have estimated
the sensitivity of the present system by using Human Serum
Albumin (HSA), a standard protein procured from Sigma
Aldrich. The protein proﬁle of Human Serum Albumin
(HSA) in diﬀerent concentrations and calibration graph
prepared out of these data are shown in Figures 1(a) and
1(b), respectively. From the Figure 1(b),w eh a v ee v a l u a t e d
the limit of detection of HSA as 11.6 femtomoles.
The mean protein proﬁles of the normal and malignant
(stage II–IV) tissue homogenates are shown in Figure 2,
illustrating the changes occurring in the protein proﬁle as we
move from normal to stage IV.
3.2. PCA of Combined Data. Figure 3 shows the plot of sam-
ple number versus scores for factor 1 for PCA of all the sam-
ples combined. It is clear from Figure 3 that the “NORMAL”
and “MALIGNANT” groups form clusters falling in diﬀerent4 The Scientiﬁc World Journal
0
0.1
0.2
0.3
0.4
0
0.1
0.2
0.3
0.4
0
0.1
0.2
0.3
0.4
0
500 1000 1500  2000  2500  3000 
500  1000  1500  2000  2500  3000 
500 1000  1500  2000  2500  3000 
500  1000  1500  2000  2500  3000 
(a)
(b)
(c)
(d)
(e)
Time (seconds)
500 1000  1500  2000  2500  3000 
1594
1861, 1893 0.1
0.2
0.3
0.4
I
n
t
e
n
s
i
t
y
 
(
a
.
u
.
)
I
n
t
e
n
s
i
t
y
 
(
a
.
u
.
)
I
n
t
e
n
s
i
t
y
 
(
a
.
u
.
)
I
n
t
e
n
s
i
t
y
 
(
a
.
u
.
)
I
n
t
e
n
s
i
t
y
 
(
a
.
u
.
)
0
0.5
1
1.5
2
2.5
Figure 2: Mean protein proﬁles of cervical tissue homogenates: (a) normal (solid) and malignant (dotted); (b–e) expanded scale of protein
proﬁles of tissue samples: (b) normal, (c) Stage II, (d) Stage III, and (e) Stage IV.
ranges of Factor 1 score. All the normal samples are having
onecloselyspacedclusterofscorevalueslyingin betweenthe
region 0.1–1.15. Many of the malignant samples have their
scores on the negative side of the plot except for 9 samples.
Score values of the nine malignant samples with positive
scores were found to be less, below 0.05.
As mentioned earlier, to provide a more objective diag-
nosis, PCA was repeated with pathologically certiﬁed cal-
ibration sets of normal and malignant samples. The results
of Match/No Match with normal and malignant calibration
sets are shown in Table 2. Every sample from the data set
is tested for the Match/No match condition; the samples of
the calibration set retrospectively (by rotating them out one
by one), and all other samples prospectively by matching
against the standard set. The result of PCA with a standard
calibration set of Stage III samples is shown in Table 3.
3.3. Diagnostic Accuracy. Receiver Operating Characteristic
(ROC) curves for normal and malignant calibration sets
are shown in Figures 4(a) and 5(a),r e s p e c t i v e l y .T h eR O C -
AUC for normal and malignant sets were found to be 0.999
and 0.867, respectively. The Youden’s index plots for normal
and malignant calibration sets is shown in Figures 4(b) and
5(b). The optimum threshold for both calibration sets are
estimated as 2 M distance. For higher M distance (M>2)
the results will not improve for the presented data set. Ideal
operating points are marked with an arrow in Figures 4(b)
and 5(b) for normal and malignant sets, respectively.The Scientiﬁc World Journal 5
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Figure 4: (a) Receiver Operating Characteristic (ROC) curve and (b) Youden’s index curve for normal calibration set.
4. Discussion
From Figure 2 it is seen that many of the proteins present
only in small amounts in the normal tissue samples are ex-
pressed much more even in the Stage II samples, and many
new proteins also have appeared. As the malignancy pro-
gresses these proﬁles change drastically from stage II to IV
giving proﬁles which are very diﬀerent in the diﬀerent stages
of the disease. From the visual analysis of the protein proﬁles
itself it is clear that many proteins which appear even in the
initial 600seconds period are expressed more (some even
showing twice as intense as that of 1594 peak) compared
to normal tissue. The 1861 and 1893 peaks in all the stages
of the cancer are much more intensiﬁed. These and other
peaks (example 250seconds, 2600seconds), connected with
the dotted lines in Figure 2 m a yp o s s i b l ys e r v ea sg o o d
markers, after identiﬁcation, for early detection and staging.
The relative intensities of these peaks are found to be almost
similar to that of 1594 peak. The region from 2050–3000
seconds also shows more intense peaks.
The score values of the normal samples show that
(Figure 3) at least in the age group studied; the cervical tissue
has more or less very similar protein composition, irrespec-
tive of age, physiological/social condition, life style like food
habits, and so forth. This provides the important possibility
of identifying any change from normalcy in the cervix. The6 The Scientiﬁc World Journal
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Figure 5: (a) Receiver Operating Characteristic (ROC) curve and (b) Youden’s index curve for malignant calibration set.
Table 2:Discriminateanalysiswithnormalandmalignantstandard
set.
PCA results for normal calibration set
Sample
number Limit Tests M Distance Spec Residual
1 FAIL 79.79 22.70
2 FAIL 10.27 3.12
3–15 PASS 0.42–1.752 0.12–0.778
16–44 FAIL 95.59–3154.71 27.176–974.01
PCA results for malignant calibration set
1 FAIL 2.017 153.097
2 FAIL 2.764 185.830
3–15 FAIL 2.97–3.32 193.60–208.19
16–33 PASS 0.42–1.24 10.04–99.47
34 FAIL 2.222 159.648
35–44 PASS 0.63–1.166 35.00–140.22
scores for the malignant group, on the other hand, are highly
dispersed, presumably because of the fact that the samples
are from diﬀerent stages of disease. So it is clear from the plot
that the score values alone can discriminate between normal
and malignant samples, with a high degree of speciﬁcity and
sensitivity.
From Table 2, for the normal standard set, it is observed
that except for the ﬁrst two normal samples, all the other
samples are showing match result. The two nonmatching
normal samples though not matching with normal standard
set, gave M distance and spectral residual much smaller
than that for malignant samples. All the malignant samples,
irrespective of the stage of cancer, were correctly identiﬁed as
not normal, by giving FAIL result. PCA results with malig-
nant calibration set show that, except for one, all malignant
samples matched with the malignant set giving PASS result.
Table 3: Discriminate analysis with standard stage III samples.
Sample
number
Limit
Tests
M
Distance Spec Residual
1–15 FAIL 2.25–2.95 34.08−43.37
16−22
23, 24
FAIL
FAIL
2.05–31.35
6.93, 24.3
34.80–422.70
104.38, 329.14
25, 26 PASS 1.05, 0.65 8.89, 7.50
27 FAIL 42.33 567.88
28−34 PASS 0.56–1.29 0.19–23.67
35 FAIL 11.49 166.55
36–39 PASS 0.65–1.59 5.95–25.8
40 FAIL 12.21 172.93
41 PASS 0.63 89.12
42–44 FAIL 2.05–13.67 36.92–194.07
All the normal samples, including those which were found to
be not matching with the normal standard set, were found
to give FAIL and did not match with the malignant standard
set. The results with the normal and malignant standard set
show that the method of discrimination by matching with
both the calibration sets gives a very consistent diagnosis.
The sensitivity of 100%, 96% and speciﬁcity of 88%, 100%
were achieved by using normal and malignant standard set
samples, respectively. From Table 3 it is clear that, except for
ﬁve out of the 19 Stage III samples, all other samples are
classiﬁed correctly using standard set of Stage III samples. All
ﬁfteen normal samples, all Stage II samples, 2 premalignant
samples, and one Stage IV sample were found to give FAIL
result. Though there are only few samples of early stages
(CIN, CIS) in the present study, it still shows that protein
proﬁling can discriminate these from advanced stages.
Though it is always desirable to identify and characterize
thenumberofproteinsobservedinthepresentstudieswhichThe Scientiﬁc World Journal 7
show noticeable change from normal through various stages
of malignancy, as potential tumor markers, it is very well
recognized now that multiparametric protein proﬁle anal-
ysis, may possibly be the most promising method for early
detection and staging of various types of malignancies [20].
Moreover,apatternofmultiplemarkerscanachieveagreater
conﬁdence level in early detection, staging, and followup,
compared to a single marker estimation by immunoassay
methods, where competing reactions as well as presence
under conditions like pregnancy, hormone therapy, and so
forth can mask the actual estimated amount.
5. Conclusions
Principal Component Analysis of protein proﬁles of cervical
tissue samples recorded using the HPLC combined with
Laser Induced Fluorescence (HPLC-LIF) technique gives
very good diagnostic results. Both the standard sets from
the normal and malignant samples gave consistent results.
Speciﬁcity and sensitivity of the analysis are found to be
very high, nearly (100%). Receiver Operating Characteristic
(ROC) and Youden’s index curves for both normal and
malignant standard sets show good diagnostic accuracy as
indicated by the high AUC values. The estimated ideal
cutoﬀ threshold is 2M distance for both calibration sets. It
should be mentioned here that, unlike histopathology, where
heterogeneity of the tissue samples and operator subjectivity
may lead to possible errors, the protein proﬁling of tissue
samples, using optical spectroscopic methods can provide
objective diagnosis of cervical cancer. Though these results
have to be validated further with much larger sets of samples,
the method discussed here can be adopted as a routine
technique for objective diagnosis of cervical cancer.
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